Intrepid Financial Planning Group LLC Sells 1,660 Shares of Novo Nordisk A/S (NYSE:NVO)

Intrepid Financial Planning Group LLC trimmed its stake in Novo Nordisk A/S (NYSE:NVO) by 12.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 11,788 shares of the company’s stock after selling 1,660 shares during the quarter. Intrepid Financial Planning Group LLC’s holdings in Novo Nordisk A/S were worth $1,404,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Verus Capital Partners LLC raised its stake in shares of Novo Nordisk A/S by 27.6% during the 3rd quarter. Verus Capital Partners LLC now owns 6,509 shares of the company’s stock worth $775,000 after acquiring an additional 1,408 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its holdings in Novo Nordisk A/S by 57.8% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 10,275 shares of the company’s stock worth $1,243,000 after purchasing an additional 3,762 shares during the last quarter. Apollon Wealth Management LLC increased its position in shares of Novo Nordisk A/S by 2.4% during the third quarter. Apollon Wealth Management LLC now owns 38,835 shares of the company’s stock worth $4,624,000 after purchasing an additional 906 shares in the last quarter. Buckingham Capital Management Inc. purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $3,874,000. Finally, Venturi Wealth Management LLC boosted its position in shares of Novo Nordisk A/S by 16.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 37,232 shares of the company’s stock worth $4,433,000 after purchasing an additional 5,220 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Up 1.8 %

Shares of NYSE:NVO opened at $109.11 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The stock has a market cap of $489.63 billion, a price-to-earnings ratio of 35.31, a PEG ratio of 1.48 and a beta of 0.42. The business has a 50-day moving average price of $120.82 and a 200-day moving average price of $130.22.

Analyst Ratings Changes

Several brokerages recently issued reports on NVO. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and a consensus price target of $144.50.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.